Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.54 |
| ▸ | SYK | P43405 | 5/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895532 | 0.86 | CNR2 (0.52) | CNR2GRM5CDK4 | |
| SCHEMBL14045886 | 0.85 | SYK (0.50) | CNR2SYKPTK2CDC7MAOB | |
| SCHEMBL4886236 | 0.85 | CNR2 (0.53) | CNR2SYK | |
| SCHEMBL14026161 | 0.83 | CNR2 (0.58) | CNR2SYKPTK2CDC7MAOB | |
| SCHEMBL4893836 | 0.82 | CNR2 (0.63) | CNR2SYKPTK2CDC7MAOB | |
| SCHEMBL14026150 | 0.81 | CNR2 (0.55) | CNR2SYKPTK2CDC7MAOB | |
| SCHEMBL14045927 | 0.81 | CNR2 (0.51) | CNR2SYK | |
| Formic Acid SCHEMBL4895900 | 0.81 | CNR2 (0.57) | CNR2SYKPTK2CDC7MAOB | |
| Formic Acid SCHEMBL4894255 | 0.79 | CNR2 (0.55) | CNR2SYKPTK2CDC7MAOB | |
| SCHEMBL4893763 | 0.78 | CNR2 (0.55) | CNR2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | CNR2, CNR1, P2RY2 | CNR2 1/4885SYK 2878/4885PTK2 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.